Cytosorbents Corporation (NASDAQ:CTSO) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Cytosorbents Corporation (NASDAQ:CTSO) posted its earnings results on Monday. The medical research company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02, Bloomberg Earnings reports. Cytosorbents Corporation had a negative return on equity of 1,426.21% and a negative net margin of 108.69%.
Shares of Cytosorbents Corporation (NASDAQ CTSO) traded up 3.26% during trading on Monday, hitting $4.75. The stock had a trading volume of 163,008 shares. The stock’s 50-day moving average price is $4.53 and its 200 day moving average price is $4.90. The stock’s market cap is $133.51 million. Cytosorbents Corporation has a one year low of $3.30 and a one year high of $6.90.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/07/cytosorbents-corporation-nasdaqctso-posts-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.
In other news, insider Phillip P. Chan acquired 6,300 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was bought at an average price of $4.00 per share, with a total value of $25,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have bought 17,500 shares of company stock valued at $70,620. Company insiders own 5.60% of the company’s stock.
Several equities analysts have recently issued reports on CTSO shares. B. Riley reiterated a “buy” rating and set a $11.25 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, April 11th. Maxim Group reiterated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents Corporation in a research report on Wednesday, April 19th. Aegis reiterated a “buy” rating and set a $9.00 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, May 9th. Finally, Cowen and Company started coverage on Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $12.38.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.